Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | BRD4 | O60885 | 2/20 | 0.43 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.43 |
| ▸ | HMOX1 | P09601 | 1/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.39 |
| ▸ | DPP4 | P27487 | 1/20 | 0.38 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.38 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.38 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.38 |
| ▸ | RET | P07949 | 2/20 | 0.38 |
| ▸ | EP300 | Q09472 | 1/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.37 |
| ▸ | CFTR | P13569 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4514777 | 0.85 | MAPK1 (0.47) | MAPK1NPC1BRD4CREBBPHMOX1 | |
| SCHEMBL2977256 | 0.83 | MAPK1 (0.57) | MAPK1NPC1BRD4CREBBPGPR119 | |
| SCHEMBL1336775 | 0.82 | MAPK1 (0.56) | MAPK1NPC1BRD4CREBBPHMOX1 | |
| SCHEMBL4762437 | 0.81 | MAPK1 (0.72) | MAPK1NPC1BRD4CREBBPP2RX7 | |
| SCHEMBL16836084 | 0.80 | GPR119 (0.50) | MAPK1GPR119P2RX7RETESR2 | |
| SCHEMBL4712216 | 0.79 | MAPK1 (0.56) | MAPK1NPC1BRD4CREBBPDPP4 | |
| SCHEMBL2975661 | 0.79 | MAPK1 (0.56) | MAPK1NPC1BRD4CREBBPDPP4 | |
| SCHEMBL4083458 | 0.79 | HMOX1 (0.51) | MAPK1HMOX1 | |
| SCHEMBL2966970 | 0.79 | MAPK1 (0.49) | MAPK1NPC1BRD4CREBBPHMOX1 | |
| SCHEMBL10095067 | 0.79 | BRD4 (0.67) | MAPK1NPC1BRD4CREBBPP2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090118274-A1 | MONOCYCLIC AMINOPROPYL TETRAHYDRO-PYRAZOLO-PYRIDINE MODULATORS OF CATHEPSIN S | SUNESIS PHARMACEUTICALS, INC. | 2009-05-07 | — | — | US | disclosed |
| US-20080269241-A1 | BICYCLIC AMINOPROPYL TETRAHYDRO-PYRAZOLO-PYRIDINE MODULATORS OF CATHEPSIN S | SUNESIS PHARMACEUTICALS, INC. | 2008-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269241-A1 | BICYCLIC AMINOPROPYL TETRAHYDRO-PYRAZOLO-PYRIDINE MODULATORS OF CATHEPSIN S | CTSS, CTSK, CTSZ | MAPK1 2735/4885NPC1 1160/4885BRD4 118/4885 |
| US-20090118274-A1 | MONOCYCLIC AMINOPROPYL TETRAHYDRO-PYRAZOLO-PYRIDINE MODULATORS OF CATHEPSIN S | CTSS, CTSK, CTSZ | MAPK1 2323/4885NPC1 1115/4885BRD4 337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.